Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

Phase 2
Recruiting
Conditions
CLL
Interventions
Drug: Acalabrutinib
Drug: Venetoclax
First Posted Date
2019-03-11
Last Posted Date
2023-12-04
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
212
Registration Number
NCT03868722
Locations
🇸🇪

Örebro University Hospital, Örebro, Sweden

🇸🇪

Karolinska University Hospital, Stockholm, Sweden

🇩🇰

Herlev og Gentofte Hospital, Herlev, Denmark

and more 4 locations

Venetoclax and Lintuzumab-Ac225 in AML Patients

First Posted Date
2019-03-08
Last Posted Date
2023-08-04
Lead Sponsor
Actinium Pharmaceuticals
Target Recruit Count
38
Registration Number
NCT03867682
Locations
🇺🇸

University of California, Los Angeles, California, United States

🇺🇸

Weill Cornell Medicine, New York, New York, United States

🇺🇸

University of Louisville, Louisville, Kentucky, United States

and more 2 locations

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2019-03-05
Last Posted Date
2024-06-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT03862157
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

First Posted Date
2019-02-27
Last Posted Date
2019-03-26
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT03856112

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Phase 1
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Decitabine
Drug: Venetoclax
First Posted Date
2019-02-18
Last Posted Date
2024-11-11
Lead Sponsor
University of Chicago
Target Recruit Count
26
Registration Number
NCT03844815
Locations
🇺🇸

University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

First Posted Date
2019-02-18
Last Posted Date
2024-12-06
Lead Sponsor
AbbVie
Target Recruit Count
165
Registration Number
NCT03844048
Locations
🇯🇵

Duplicate_National Hospital Organization Mito Medical Center /ID# 241986, Higashi Ibaraki-gun, Ibaraki, Japan

🇺🇸

University of Arizona Cancer Center - Tucson /ID# 210548, Tucson, Arizona, United States

🇺🇸

UCLA Santa Monica Hematology Oncology /ID# 210551, Los Angeles, California, United States

and more 53 locations

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

First Posted Date
2019-02-11
Last Posted Date
2024-09-30
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
984
Registration Number
NCT03836261
Locations
🇬🇧

Research Site, Wolverhampton, United Kingdom

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

First Posted Date
2019-02-08
Last Posted Date
2024-08-28
Lead Sponsor
PrECOG, LLC.
Target Recruit Count
33
Registration Number
NCT03834688
Locations
🇺🇸

Carle Cancer Center, Urbana, Illinois, United States

🇺🇸

Indiana University Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 4 locations

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Phase 1
Recruiting
Conditions
Leukemia
Interventions
Drug: Vyxeos
Drug: Venetoclax
First Posted Date
2019-02-01
Last Posted Date
2024-01-25
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
21
Registration Number
NCT03826992
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

First Posted Date
2019-01-31
Last Posted Date
2024-11-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
230
Registration Number
NCT03824483
Locations
🇺🇸

Northwestern University, Evanston, Illinois, United States

🇺🇸

Massachusetts General Hospital (Data Collection and Specimen Analysis), Boston, Massachusetts, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy